Laboratorios Farmaceuticos Rovi (ES:ROVI) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Laboratorios Farmacéuticos ROVI has successfully passed all proposed resolutions during its Ordinary General Shareholders’ Meeting, including the approval of annual accounts, management reports, a dividend payout, and the re-election of board members and auditors for the upcoming year. Shareholders endorsed a dividend distribution equivalent to 35% of the 2023 consolidated profit, and confirmed KPMG Auditores, S.L. as the company’s auditors for 2024. The company will also implement a Long-Term Incentive Plan and a share capital reduction by amortizing its own shares.
For further insights into ES:ROVI stock, check out TipRanks’ Stock Analysis page.
